Luis Martinez, MD
Adult Medicine · Fresno, CANPI 1134423684
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $512 and has fallen 70.9% since, to $149 in 2025.
Across 103 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$323
- Johnson & Johnson$277
- GSK$183
- AstraZeneca$147
- Merck$137
- Novo Nordisk$127
- plus $495 from 15 others
What the payments were for
- Food & beverage$1,689100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $323 |
| Johnson & Johnson | 10 | $277 |
| GSK | 15 | $183 |
| AstraZeneca | 2 | $147 |
| Merck | 25 | $137 |
| Novo Nordisk | 8 | $127 |
| Abbott | 5 | $107 |
| Amgen | 2 | $64 |
| Kowa Pharmaceuticals America, Inc. | 3 | $60 |
| Lilly USA, LLC | 3 | $51 |
| Pfizer | 2 | $39 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Novartis | 1 | $23 |
| Boehringer Ingelheim | 1 | $23 |
| Bayer | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Mannkind Corporation | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Aimmune Therapeutics, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,689 in reported general payments places this provider in the 80th percentile of 221 adult medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 47 | $57,930 |
| OzempicSemaglutide | 40 | $55,706 |
| Xigduo XrDapaglifloz Propaned/Metformin | 32 | $36,700 |
| EliquisApixaban | 29 | $32,832 |
| FarxigaDapagliflozin Propanediol | 24 | $32,499 |
| MounjaroTirzepatide | 26 | $30,117 |
| JardianceEmpagliflozin | 19 | $27,437 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $25,493 |
| CreonLipase/Protease/Amylase | 15 | $18,707 |
| MyrbetriqMirabegron | 14 | $16,667 |
| XareltoRivaroxaban | 16 | $15,247 |
| VascepaIcosapent Ethyl | 23 | $14,114 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $11,779 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $9,883 |
| Humalog Kwikpen U-100Insulin Lispro | 26 | $8,730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $137 | $57,93047 claims |
| Novo NordiskOzempic | $127 | $55,70640 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $183 | $37,27246 claims |
| AstraZenecaFarxiga, Symbicort | $147 | $36,88836 claims |
| PfizerEliquis | $39 | $32,83229 claims |
| Lilly USA, LLCMounjaro | $51 | $30,11726 claims |
| Boehringer IngelheimJardiance | $23 | $27,43719 claims |
| AbbVieCreon | $323 | $18,70715 claims |
| Johnson & JohnsonXarelto | $277 | $15,24716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 221 adult medicine providers in California.
Other adult medicine in Fresno
- Albert MuFresno$2K
- Gessie LurlayFresno$1K
- Susan HutchinsonLaguna Hills$1M
- Natalia GuzmanLos Angeles$583K
- Richard FauselRancho Mirage$30K
- Benedicto EstoestaValley Springs$22K
- Antoine DipsiaW. Sacramento$21K
- Patrick WelchArroyo Grande$20K
- Craig BobsonManteca$19K
- Tin WongLos Angeles$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.